Highlights

ENDO Faculty Interviews

 
Using SGLT2 Inhibitors in Patients With T1DM: PRO
 
47
What is the background of using SGLT2 Inhibitors and why we may consider using them in patients with T1DM?
273
Are there particular patients in whom you would consider SGLT2 inhibitors in addition to traditional insulin therapy?
438
What is the increased risk of ketoacidosis in patients that will start SGLT2 inhibitors?
535
What are some advantages of SGLT2 inhibitors if you consider another therapy, for example amylin?
 
Synthetic Hydrogels as Engineered Niches in Regenerative Medicine 
 
56
What are synthetic hydrogels?
110
How can hydrogels be useful in the context of endocrine disorders?
388
What are some of the obstacles in bringing synthetic hydrogels in human trials?
462
What are the potential applications in regenerative medicine?
 
How Much Surveillance Is Too Much?
 
48
What are the take home message of your presentation?
105
What clinical parameters are used to classify patients as disease-free?
405
Can you tell us about active surveillance?
532
How can one define the optimal surveillance strategy?
 
Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline
 
55
Can you tell us about the new Endocrine Society Clinical Practice Guidelines for lipid management and how they are different from previous versions?
133
Can you tell us about new approaches and therapies?
210
What about other endocrine disorders that we should be paying attention to in terms of lipid management?
298
Are there any guidelines with respect to younger patients?
390
Are there specific targets?
 
Early Follow-up of Atypical Thyroiditis Induced by SARS-CoV-2
 
51
Can you tell us about your study?
225
Do you think this could be a manifestation of a direct viral infection of the thyroid?
353
Did these patients have other laboratory evidence of subacute thyroiditis?
682
What are the perspectives of therapy for these patients?
 
Using SGLT2 Inhibitors in Patients With T1DM: CON
 
48
What is the rationale for using SGLT2 inhibitors in patients with T1DM?
339
What is the experience in countries where SGLT2 inhibitors have been approved for use?
 
“High Risk” Features of Differentiated Thyroid Cancer Are Commonly Found in Autopsy Studies: Implications for the ATA Guidelines
 
44
What is the background of your study and what you found?
337
What are the current practice guidelines for high risk features?
454
How do you think it would change clinical practice?
523
Is there any way to make any of these diagnoses prior to surgery and improve diagnostic capabilities?
 
What Pediatric Endocrinologists Need to Know About Dyslipidemia
 
47
What are some of the common lipid disorders in pediatric patients?
189
Are there specific clinical features that will cause you to screen for lipid disorders?
319
What is the prevalence of FH hypercholesterolemia in children?
384
Is there a role for lifestyle changes in pediatric patients with lipid disorders?

Post test How Can We Help? Feedback